Quantcast
Channel: Antabio
Browsing latest articles
Browse All 18 View Live

Antabio’s Novel Metallo β-Lactamase Inhibitor to be presented at the ASM...

Two presentations will focus on Antabio’s ANT2681, a novel Metallo β-Lactamase Inhibitor that restores the efficacy of Meropenem against clinical strains of NDM-producing CRE Labège, France, June 05,...

View Article



Antabio Receives QIDP Designation from the U.S. FDA for the Development of...

Antabio Receives QIDP Designation from the U.S. FDA for the Development of Its Metallo Beta-Lactamase inhibitor ANT2681 Labège, France, 21 June 2019. Antabio SAS, a private biopharmaceutical company...

View Article

Antabio applauds the new mechanism for reimbursement of antibiotics set up by...

Antabio applauds the new mechanism for reimbursement of antibiotics set up by CMS in the US On August 2, 2019, the US government announced several significant changes to hospital antibiotic...

View Article

Antabio Awarded $4.4 Million from CARB-X for the Further Development of its...

The funding will be used to advance Antabio’s Pseudomonas Elastase Inhibitor (PEi) program up to completion of non-GLP preclinical studies. Download the full press release hereTélécharger le...

View Article

Antabio Receives FDA Qualified Infectious Disease Product (QIDP) Designation...

Antabio SAS announced today that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to Antabio’s MEM-ANT3310, a combination of meropenem...

View Article


Antabio Awarded EUR 0.9 million funding from the Occitanie Region to support...

Télécharger le communiqué en version française The post Antabio Awarded EUR 0.9 million funding from the Occitanie Region to support the Preclinical Development of MEM-ANT3310, Antabio’s Novel...

View Article

Launch of ARPEGE, a French multidisciplinary consortium to fight antibiotic...

Led by Antabio, acting jointly with bioMérieux, Hospices Civils de Lyon, and Toulouse School of Economics, the four-year ARPEGE project has been funded by the French government with nearly €9 million...

View Article

Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of...

MEM-ANT3310 has the potential to become the next standard of care for life-threatening infections due to its unique coverage including carbapenem-resistant Enterobacterales and Acinetobacter baumannii....

View Article


Antabio is seeking a Regulatory Manager

Antabio is a Labège, France-based biopharmaceutical company dedicated to the discovery of first-in-class small molecule compounds to treat severe infections caused by antibiotic-resistant bacterial...

View Article


ANTABIO Raises €25 million in Series B Financing

Led by the AMR Action Fund, with subscriptions from the EIC Fund and from Antabio’s historical investors, the financing will be used to support the clinical development of MEM-ANT3310 up to completion...

View Article
Browsing latest articles
Browse All 18 View Live




Latest Images